News Image

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Provided By GlobeNewswire

Last update: May 12, 2025

ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that it will host a virtual R&D call, titled “Deucrictibant: Beyond HAE Type 1/2” on Wednesday, June 4, at 8:00 a.m. ET/14:00 CET.

Read more at globenewswire.com

PHARVARIS NV

NASDAQ:PHVS (7/22/2025, 8:00:00 PM)

After market: 21.49 -1.63 (-7.05%)

23.12

-0.72 (-3.02%)



Find more stocks in the Stock Screener

Follow ChartMill for more